🧬 Adoptive T-cell therapy cleared persistent SARS-CoV-2 in 20 of 23 immunocompromised patients (87%) in a GeroScience study, with 90.9% and 83.3% clearance across the two arms. These patients did not have Long COVID, so this is a reason to test the approach in trials, not a treatment to use today.
https://t.co/zl6m0QucRC
@amyrochlin@dbkell Don't you need more patients to test? If so, please let me know. I have some very specific symptoms caused by very specific activity.
@AdamMancini4 Hi Adam, I am a long time subscriber, and have a couple questions. Do I ask here or should I email or Substack? If you take an entry with a 10-15 points in risk, but your next resistance is < 10 points, do you still take the trade?
@insane_analyst you must be missing the major rotation into beaten down stocks on the DIA/IWM trading with PE's 8 that are excellent companies... Meanwhile, sell the tech names at once in the lifetime PE's, because the spending obviously isn't going to last.....
Calling folks in the Northeast! We’re recruiting individuals with Long COVID and brain fog or cognitive difficulties for a Yale research study involving an MRI with gadolinium contrast. See the flyer for details, and please share! #longcovid